Age, sex, activity, genetic phenotype, stress, disease (eg, achlorhydria, malabsorption syndromes), or previous GI surgery can affect drug bioavailability.

年龄、性别、活动情况、遗传表型、应激、疾病（如胃酸,养不良综合征）或既往胃肠手术等均影响药物的生物利用度。

The transportability through BBB and bioavailability of the inhibitors will be the focus by the systemafic bioassay in vivo.

指出以后的点是进行系统深入的生物体内评价,解决药物透过血脑屏障和生物利用度等问题。

Age, sex, activity, genetic phenotype, stress, disease (eg, achlorhydria, malabsorption syndromes), or previous GI surgery can affect drug bioavailability.

年龄、性别、况、遗传表型、应激、疾病（如胃酸缺乏,营养不良综合征）或既往胃肠手术等均影响药物的生物利用度。

The transportability through BBB and bioavailability of the inhibitors will be the focus by the systemafic bioassay in vivo.

指出以后的工作重点是进行系统深入的生物体,解决药物透过血脑屏障和生物利用度等问题。

Age, sex, activity, genetic phenotype, stress, disease (eg, achlorhydria, malabsorption syndromes), or previous GI surgery can affect drug bioavailability.

年龄、性别、活动情况、遗传表型、应激、疾（酸缺乏,营养不良综合征）或既往肠手术等均影响药物的生物利用度。

The transportability through BBB and bioavailability of the inhibitors will be the focus by the systemafic bioassay in vivo.

指出以后的工作重点系统深入的生物体内评价,解决药物透过血脑屏障和生物利用度等问题。

Age, sex, activity, genetic phenotype, stress, disease (eg, achlorhydria, malabsorption syndromes), or previous GI surgery can affect drug bioavailability.

年龄、性别、活动情况、遗传表型、应激、疾病（如酸缺乏,营养不良综合征）或既往手术等均影响药利用度。

The transportability through BBB and bioavailability of the inhibitors will be the focus by the systemafic bioassay in vivo.

指出以后工作重点是进行系统深入体内评价,解决药透过血脑屏障和利用度等问题。

Age, sex, activity, genetic phenotype, stress, disease (eg, achlorhydria, malabsorption syndromes), or previous GI surgery can affect drug bioavailability.

年龄、性别、活动情况、遗传表型、应激、疾病（如胃酸缺乏,营养合征）或既往胃肠手术等均影响药物的生物利用度。

The transportability through BBB and bioavailability of the inhibitors will be the focus by the systemafic bioassay in vivo.

指的工作重点是进行系统深入的生物体内评价,解决药物透过血脑屏障和生物利用度等问题。

Age, sex, activity, genetic phenotype, stress, disease (eg, achlorhydria, malabsorption syndromes), or previous GI surgery can affect drug bioavailability.

年龄、性别、活动情况、遗传表型、应激、疾病（如胃酸缺乏,营养不良综合征）或既往胃肠手术等均影响药的度。

The transportability through BBB and bioavailability of the inhibitors will be the focus by the systemafic bioassay in vivo.

指出以后的工作重点是进行系统深入的体内评价,解决药透过血脑屏障度等问题。

Age, sex, activity, genetic phenotype, stress, disease (eg, achlorhydria, malabsorption syndromes), or previous GI surgery can affect drug bioavailability.

年龄、性、情况、遗传表型、应激、疾病（如胃酸缺乏,营养不良综合征）或既往胃肠手术等均影响药物的生物利用度。

The transportability through BBB and bioavailability of the inhibitors will be the focus by the systemafic bioassay in vivo.

指出以后的工作重点是进行系统深入的生物体内,决药物透过血脑屏障和生物利用度等问题。

Age, sex, activity, genetic phenotype, stress, disease (eg, achlorhydria, malabsorption syndromes), or previous GI surgery can affect drug bioavailability.

年龄、性别、活动情况、遗传表型、应激、疾病（如胃酸缺乏,良综合征）或既往胃肠手术等均影响药物生物利用度。

The transportability through BBB and bioavailability of the inhibitors will be the focus by the systemafic bioassay in vivo.

指出以作重点是进行系统深入生物体内评价,解决药物透过血脑屏障和生物利用度等问题。

Age, sex, activity, genetic phenotype, stress, disease (eg, achlorhydria, malabsorption syndromes), or previous GI surgery can affect drug bioavailability.

年龄、性别、活动情况、遗传表型、应激、疾病（如酸缺乏,营养不良综合征）或既手术等均影响药利用度。

The transportability through BBB and bioavailability of the inhibitors will be the focus by the systemafic bioassay in vivo.

指出以后工作重点是进行系统深入体内评价,解决药透过血脑屏障和利用度等问题。